Dr. Reddy's Laboratories
238 hedge funds and large institutions have $1.82B invested in Dr. Reddy's Laboratories in 2026 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 75 increasing their positions, 97 reducing their positions, and 37 closing their positions.
9% more capital invested
Capital invested by funds: $1.67B → $1.82B (+$152M)
0.61% more ownership
Funds ownership: 14.43% → 15.05% (+0.61%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 249 → 238 (-11)
16% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 37
23% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 97
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$38.1M |
| 2 |
Morgan Stanley
New York
|
+$21.1M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$19.4M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$16M |
| 5 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$13.5M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$10.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$8.62M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.21M |
| 5 |
Renaissance Technologies
New York
|
-$6.92M |
RDY Hedge Fund Activity: Q2 2026 in Review
238 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q2 2026, worth a combined $1.82B — up 9.1% from $1.67B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of RDY and 31 opened new positions — a net loss of 6 holders — while 97 trimmed existing stakes and 75 added.
The largest buyer was Nuveen, opening a new position worth an estimated $38.1M. The largest seller was BlackRock, cutting an estimated $13.5M.
- 238 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q2 2026, down from 249 in Q1 2026.
- Funds reported $1.82B of Dr. Reddy's Laboratories stock for Q2 2026, up 9.1% quarter-over-quarter.
- 31 funds opened new Dr. Reddy's Laboratories positions in Q2 2026 and 37 closed out, a net change of -6 holders.
- The largest Dr. Reddy's Laboratories buyer in Q2 2026 was Nuveen, an estimated $38.1M added.
- The largest Dr. Reddy's Laboratories seller in Q2 2026 was BlackRock, an estimated $13.5M sold.
Based on aggregated 13F filings for Q2 2026.